10x asked the US District Court for the Northern District of California to dismiss a suit, while another district court judge denied a 10x motion to dismiss.
The platform can detect a single virus in more than 1,000 samples at a time or more than 160 viruses, including SARS-CoV-2, in a small number of samples.
Fluidigm's Biomark HD microfluidic platform will enable more than 180,000 real-time PCR tests to be run over the next 90 days to potentially support COVID-19 screening.
The Stanford University spinout claims it can get three times the nucleic acid yield as column- or magnetic bead-based methods, with less damage to the molecules.
Bioinformatics firm Next Gen Diagnostics will integrate Fluidigm's Juno microfluidic sample prep system into its workflow for pathogen whole-genome sequencing.
The commission plans to bar Bio-Rad from importing certain single-cell products, potentially including the ddSeq Single-Cell Isolator and ddSeq cartridges.
10x Genomics sued Harvard University and 1CellBio, a competing single-cell technology firm, in 2018 over licenses for patents granted to both companies.
Direct-to-consumer genetic testing companies are searching for a genetic reason for why some people, but not others, become gravely ill with COVID-19, the Detroit Free Press reports.
In PNAS this week: forward genetics-base analysis of retinal development, interactions of T cell receptors with neoantigens in colorectal cancer, and more.
